PF 06266047

Drug Profile

PF 06266047

Alternative Names: PF06266047; PF6266047

Latest Information Update: 15 Jun 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Schizophrenia

Most Recent Events

  • 01 May 2016 Pfizer completes a phase I trial in Schizophrenia (In volunteers) in Belgium (NCT02539550)
  • 08 Sep 2015 Pfizer plans a phase I trial in Undefined indication (In volunteers) in Belgium (NCT02539550)
  • 01 Sep 2015 Preclinical trials in Undefined indication in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top